A Prospective, Multicentre, Randomised, Double-blind, Placebo Controlled Study With Oral ST10-021 for the Treatment of Iron Deficiency Anaemia in Subjects With Quiescent Ulcerative Colitis Where Oral Ferrous Preparations Have Failed or Cannot be Used (AEGIS 1)

Trial Profile

A Prospective, Multicentre, Randomised, Double-blind, Placebo Controlled Study With Oral ST10-021 for the Treatment of Iron Deficiency Anaemia in Subjects With Quiescent Ulcerative Colitis Where Oral Ferrous Preparations Have Failed or Cannot be Used (AEGIS 1)

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Mar 2017

At a glance

  • Drugs Ferric maltol (Primary)
  • Indications Iron deficiency anaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms AEGIS-1
  • Sponsors Iron Therapeutics
  • Most Recent Events

    • 29 May 2016 Results of long term extension study from AEGIS 1 and AEGIS 2 trials published in the Alimentary Pharmacology and Therapeutics
    • 04 Mar 2014 Planned End Date changed from 1 Dec 2012 to 1 Sep 2014 as reported by ClinicalTrials.gov record.
    • 07 Jan 2014 Primary endpoint 'Significant superiority of ST 10 vs placbo in change in haemoglobin level over 12 weeks' has been met, according to a Shield Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top